Nutex Health (NUTX) EBITDA (2010 - 2026)

Nutex Health (NUTX) has 17 years of EBITDA data on file, last reported at $81.3 million in Q1 2026.

• Quarterly EBITDA rose 0.75% year-over-year to $81.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $276.2 million (up 31.64% YoY) and the FY2025 annual result came in at $275.6 million, up 110.89% from the prior year.
• EBITDA improved to $81.3 million in Q1 2026 per NUTX's latest filing, from $30.9 million in the prior quarter.
• The five-year high for EBITDA was $130.4 million in Q3 2025, with the low at -$428.7 million in Q3 2022.
• Average EBITDA over 5 years is $2.9 million, with a median of $5.3 million recorded in 2024.
• Year-over-year, EBITDA sank 675.7% in 2022 and jumped 5462.83% in 2025.
• Nutex Health's EBITDA stood at -$5.8 million in 2022, then slumped by 352.42% to -$26.1 million in 2023, then jumped by 536.83% to $114.2 million in 2024, then sank by 72.93% to $30.9 million in 2025, then soared by 162.84% to $81.3 million in 2026.
• Business Quant data shows NUTX's EBITDA at $81.3 million in Q1 2026, $30.9 million in Q4 2025, and $130.4 million in Q3 2025.